Dosimetric and clinical factors for predicting acute radiation oral mucositis in locally advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy with concurrent chemotherapy
Li Kaixin,Xin Peiling,Chen Yuanyuan,Chen Ming
Department of Radiation Oncology,Affiliated Quanzhou First Hospital of Fujian Medical University,Quanzhou 362000,China (Li KX,Xin PL);Department of Radiation Oncology,Zhejiang Tumor Hospital,Zhejiang Provincial Key Laboratory of Radiotherapy,Hangzhou 310000,China (Chen YY,Chen M)
Abstract： Objective To prospectively determine the dosimetric and clinical factors for predicting the risk of acute radiation oral mucositis (ROM) in patients receiving intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy for local advanced nasopharyngeal carcinoma. Methods Ninety-two patients who were treated with IMRT with concurrent chemotherapy from 2015 to 2016 for local advanced nasopharyngeal carcinoma were included in this study, and their acute ROM was scored according to the RTOG criteria. Grade ≥3 ROM was used as a surrogate marker for severe mucositis, which was defined as a toxicity endpoint. The clinical data were reviewed, and the dose-volume histograms (DVHs) of the patients were exported from the IMRT planning system. Optimal thresholds for predicting the incidence of severe ROM were evaluated by the area under the receiver operating characteristic (ROC) curve (AUC). Results The incidence of severe ROM was 21%(19/92). Weight loss and V30 of the oral mucosa were determined as the independent predictors for severe ROM (P=0.017 and 0.003, respectively). The optimal cut-off point and AUC of V30 of the oral mucosa as a predictor for severe ROM were 73.16%(0.842 sensitivity and 0.671 specificity) and 0.753(P=0.001), respectively. Conclusion Weight loss and V30 of the oral mucosa are predictors for severe ROM.
Li Kaixin,Xin Peiling,Chen Yuanyuan et al. Dosimetric and clinical factors for predicting acute radiation oral mucositis in locally advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy with concurrent chemotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(3): 255-260.
[1] Wu F,Wang RS,Lu HM,et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma:treatment outcomes of a prospective,multicentric clinical study[J].Radiother Oncol,2014,112(1):106-111.DOI:10.1016/j.radonc.2014.05.005. [2] Tan T,Lim WT,Fong KW,et al. Concurrent chemo-radiation with or without induction gemcitabine,carboplatin,and paclitaxel:a randomized,phase 2/3 trial in locally advanced nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2015,91(5):952-960.DOI:10.1016/j.ijrobp.2015.01.002. [3] Guan X,Zhu G,Wang X.Induction chemotherapy with docetaxel and nedaplatin followed by concurrent IMRT and nedaplatin for locally advanced nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2014,90(1S):S525-S526.DOI:10.1016/j.ijrobp.2014.05.1606. [4] Ma F,Jin F,Jin F.Efficacy and factor affecting outcome of induction chemotherapy combined concurrent chemoradiation therapy in 263 patients with locally advanced nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2014,90(1S):S524.DOI:10.1016/j.ijrobp.2014.05.1601. [5] Lee N,Harris J,Garden AS,et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase Ⅱ trail 0225[J].J Clin Oncol,2009,27(22):3684-3690.DOI:10.1200/JCO.2008.19.9109. [6] Sun Y,Yu XL,Luo W,et al. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy[J].Radiother Oncol,2014,110(3):390-397.DOI:10.1016/j.radonc.2013.10.035. [7] Liu ZG,Zhao Y,Tang J,et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma:a retrospective analysis[J].Oncotarget,2016,7(17):24429-24435.DOI:10.18632/oncotarget.8225. [8] Li CJ,Wang SZ,Wang SY,et al. Assessment of the effect of local application of amifostine on acute radiation-induced oral mucositis in guinea pigs[J].J Radiat Res,2014,55(5):847-854.DOI:10.1093/jrr/rru024. [9] Wu SX,Cui TT,Zhao C,et al. A prospective,randomized,multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma[J].Radiother Oncol,2010,97(1):113-118.DOI:10.1016/j.radonc.2010.08.003. [10] Antin JH,Lee SJ,Neuberg D,et al. A phase Ⅰ/Ⅱ double-blind,placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation[J].Bone Marrow Transplant,2002,29(5):373-377.DOI:10.1038/sj.bmt.1703394. [11] Mallick S,Benson R,Rath GK.Radiation induced oral mucositis:a review of current literature on prevention and management[J].Eur Arch Otorhinolaryngol,2016,273(9):2285-2293.DOI:10.1007/s00405-015-3694-6. [12] Moslemi D,Nokhandani AM,Otaghsaraei MT,et al. Management of chemo/radiation-induced oral mucositis in patients with head and neck cancer:a review of the current literature[J].Radiother Oncol,2016,120(1):13-20.DOI:10.1016/j.radonc.2016.04.001. [13] Peterson DE,Boers-Doets CB,Bensadoun RJ,et al. Management of oral and gastrointestinal mucosal injury:ESMO Clinical Practice Guidelines for diagnosis,treatment,and follow-up[J].Ann Oncol,2015,26 Suppl 5:v139-151.DOI:10.1093/annonc/mdv202. [14] Sanguineti G,Endres EJ,Gunn BG,et al. Is there a “mucosa-sparing” benefit of IMRT for head-and-neck cancer?[J].Int J Radiat Oncol Biol Phys,2006,66(3):931-938.DOI:10.1016/j.ijrobp.2006.05.060. [15] Narayan S,Lehmann J,Coleman MA,et al. Prospective evaluation to establish a dose response for clinical oral mucositis in patients undergoing head-and-neck conformal radiotherapy[J].Int J Radiat Oncol Biol Phys,2008,72(3):756-762.e4.DOI:10.1016/j.ijrobp.2008.01.060. [16] Wang ZH,Zhang SZ,Zhang ZY,et al. Protecting the oral mucosa in patients with oral tongue squamous cell carcinoma treated postoperatively with intensity-modulated radiotherapy:a randomized study[J].Laryngoscope,2012,122(2):291-298.DOI:10.1002/lary.22434. [17] Musha A,Shimada H,Shirai K,et al. Prediction of acute radiation mucositis using an oral mucosal dose surface model in carbon ion radiotherapy for head and neck tumors[J].PLoS One,2015,10(10):e0141734.DOI:10.1371/journal.pone.0141734. [18] Mazzola R,Ricchetti F,Fersino S,et al. Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment:a dose-volume analysis[J].Head Neck,2016,38(S1):E815-819.DOI:10.1002/hed.24106. [19] Bhide SA,Gulliford S,Fowler J,et al. Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy[J].Radiother Oncol,2010,97(1):86-91.DOI:10.1016/j.radonc.2010.08.013. [20] Sanguineti G,Gunn GB,Parker BC,et al. Weekly dose-volume parameters of mucosa and constrictor muscles predict the use of percutaneous endoscopic gastrostomy during exclusive intensity-modulated radiotherapy for oropharyngeal cancer[J].Int J Radiat Oncol Biol Phys,2011,79(1):52-59.DOI:10.1016/j.ijrobp.2009.10.057. [21] Xu T,Liu Y,Dou S,et al. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma:results of a randomized phase Ⅱ study[J].Oral Oncol,2015,51(9):875-879.DOI:10.1016/j.oraloncology.2015.06.008. [22] Shen LJ,Chen C,Li BF,et al. High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse:a retrospective analysis of 2433 cases[J].PLoS One,2013,8(7):e68660.DOI:10.1371/journal.pone.0068660.
2017, Vol. 26 
